Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Androgen-independent prostate cancer (PCa) remains a significant therapeutic challenge.
• Paclitaxel and docetaxel resistance are common in advanced PCa.
• ErbB receptor and AKT signaling pathways are implicated in PCa progression.

Purpose of the Study:

• To investigate the anti-tumor efficacy of co-targeting ErbB receptors and AKT in prostate cancer models.
• To evaluate this strategy in both drug-sensitive and drug-resistant PCa cell lines.
• To assess the in vivo anti-tumor activity and pharmacodynamics of dual inhibition.

Main Methods:

• Utilized PC3 and DU145 prostate cancer cell lines and their taxane-resistant derivatives.
• Employed small-molecule kinase inhibitors targeting ErbB receptors and AKT.
• Assessed in vitro anti-proliferative and pro-apoptotic effects.
• Evaluated in vivo anti-tumor responses using tumor xenografts.

Main Results:

• Synergistic anti-proliferative and enhanced pro-apoptotic effects were observed across all tested cell lines, irrespective of resistance status or PTEN expression.
• Dual targeting demonstrated enhanced anti-tumor activity in vivo.
• Pharmacodynamic discordance was noted between in vitro and in vivo models regarding AKT and ERK signaling.
• Consistent AKT inhibition was achieved both in vitro and in vivo.

Conclusions:

• Co-targeting AKT with ErbB receptors presents a promising therapeutic strategy for advanced prostate cancer.
• This approach demonstrates efficacy against both sensitive and resistant PCa, independent of PTEN status.
• Further exploration of dual targeting, potentially with other partners, is warranted for advanced PCa treatment.